anagrelide


Also found in: Wikipedia.

anagrelide

 [an-ag´rĕ-līd]
an agent used in the form of the hydrochloride salt to reduce elevated platelet counts and the risk of thrombosis in treatment of hemorrhagic thrombocythemia; administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

anagrelide

A cytoreductive agent used to manage essential thrombocythaemia and thrombocythaemia due to myeloproliferative disorders (e.g., CML, polycythemia vera) to reduce platelets, risk of thrombosis and other symptoms. It is generally regarded as a second-line therapy compared to hydroxyurea.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.

Anagrelide

An orphan drug that is approved for treating PV patients on an investigational basis. Anagrelide works by controlling the level of platelets in the blood.
Mentioned in: Polycythemia Vera
Gale Encyclopedia of Medicine. Copyright 2008 The Gale Group, Inc. All rights reserved.
References in periodicals archive ?
hirta leaves in Sprague-Dawley rats who were orally treated with Anagrelide (given for 15 days) for the induction of thrombocytopenia [22].
Anagrelide, on the other hand, is a phosphodiesterase 3 (PDE 3) inhibitor that is recommended as a 3rd-line treatment for ET after interferon-[alpha] (IFN-[alpha]) and busulfan [2].
(NASDAQ: INCY) has treated the first patient in the RESET pivotal trial evaluating ruxolitinib (Jakafi) compared to anagrelide for the treatment of patients with essential thrombocythemia (ET) who are resistant to or intolerant of hydroxyurea (HU), the company said.
Hydroxyurea, interferon alfa, and peginterferon alfa, and possibly anagrelide, have been shown to be effective for the prevention of venous thrombotic complications in patients with high-risk ET.
A 55-year-old Chinese Singaporean man with a background of Polycythemia Rubra Vera (PRV), currently on treatment with hydroxyurea and anagrelide, diabetes mellitus, and hypertension, was admitted with a four-day history of nonbilious, nonbloody vomiting accompanied with nonbloody diarrhea.
[this report] Sex Female ITP diagnosis July 1992 (45 y.o.) ITP treatment (1) PD 1 mg/kg x 3 (1st and 2nd relapse) (2) After ET dgn: (i) 3rd ITP relapse: Igs 0,4 mg/kg x 5 days + AZT (ii) 4th ITP relapse: PD + AZT ET diagnosis January 2013 JAK2 mutation Positive BM biopsy Compatible with ET (2013) MPN--ITP latency ET diagnosed after 21 years of follow-up Splenomegaly No ET treatment HU Bone marrow (BM) biopsy, dexamethasone (DXM) 40mg/day x 4 days, immunoglobulins (Igs), TTP (thrombotic thrombocytopenic purpura), ANA (anagrelide), HU (hydroxyurea), prednisone (PD), and azathioprine (AZT).
Biopharmaceutical company Galena Biopharma (NasdaqCM:GALE) Wednesday announced the regulatory pathway to advance GALE-401 (Anagrelide Controlled Release) into a pivotal Phase 3 trial for the treatment of essential thrombocythemia following the productive meeting with the US Food and Drug Administration (FDA)
SOME DRUGS THAT CAN CAUSE OR EXACERBATE HEART FAILURE Condition Drugs Arrhythmia dronedarone, flecainide, disopyramide, sotalol Cancer anthracydines and many other agents Depression citalopram, lithium Diabetes thiazolidinediones, dipeptidyl peptidase-4 inhibitors Fungal infections amphotericin B Hypertension doxazosin, diltiazem, verapamil, moxonidine Malaria chloroquine, hydroxychloroquine Migraines ergotamine, methysergide Pain prescription and nonprescription NSAIDs Parkinson's pergolide, pramipexole, bromocriptine Platelet disorders anagrelide, cilostazol Pulmonary disease bosentan, epoprostenol, albuterol Rheumatologic TNF-a inhibitors diseases
Progression of bone marrow fibrosis in patients with essential thrombocythemia and polycythemia vera during anagrelide treatment.
d, Anagrelide (5) 1mg bid, Alpha Interferon (6) 3 million daily are best options to reduce the platelet counts in E.